Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EMLNASDAQ:ME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMLEastern$23.26-2.2%$23.09$19.06▼$35.03$142.98M1.0820,911 shs4,782 shsME23andMe$0.50-35.3%$0.68$0.53▼$12.32$13.36M1.191.30 million shs29.28 million shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMLEastern-2.23%-2.27%+18.49%-19.68%-16.45%ME23andMe0.00%0.00%0.00%-81.69%-95.44%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEMLEastern1.0183 of 5 stars0.05.00.80.01.92.50.0ME23andMeN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMLEastern 0.00N/AN/AN/AME23andMe 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ME and EML Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/7/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 5/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMLEastern$271.44M0.53$2.41 per share9.66$21.24 per share1.10ME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMLEastern$8.59M-$1.32N/A∞N/A-2.26%10.44%5.42%8/4/2025 (Estimated)ME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ALatest ME and EML EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025EMLEastern$0.41$0.31-$0.10$0.32$71.33 million$63.31 million3/11/2025Q4 2024EMLEasternN/A$0.42N/A$0.26N/A$66.70 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMLEastern$0.441.89%N/AN/A N/AME23andMeN/AN/AN/AN/AN/ALatest ME and EML DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/30/2025EMLEasternquarterly$0.112.1%5/15/20255/15/20256/16/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMLEastern0.372.641.42ME23andMeN/A1.050.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMLEastern76.99%ME23andMe36.10%Insider OwnershipCompanyInsider OwnershipEMLEastern17.00%ME23andMe26.32%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMLEastern1,1906.15 million5.13 millionNot OptionableME23andMe77026.83 million19.77 millionNot OptionableME and EML HeadlinesRecent News About These Companies23andMe Data Breach Deadline: How to file a claimMay 21 at 2:25 AM | yahoo.comRegeneron to acquire 23andMe for $256M, plans to continue consumer genetics servicesMay 20 at 9:24 PM | massdevice.comBiotech company Regeneron buying 23andMe for $256 millionMay 20 at 4:21 PM | msn.com23andMe Has Found a Buyer—Here’s What Might Happen to Your Genetic DataMay 20 at 4:21 PM | observer.comWhat will happen to your genetic data after 23andMe sale?May 20 at 4:21 PM | msn.comBankrupt 23andMe to be bought by pharmaceutical company Regeneron for $256 millionMay 20 at 4:21 PM | msn.comStruggling DNA testing firm 23andMe to be bought for $256mMay 20 at 11:20 AM | msn.com23andMe bought by Regeneron in court auctionMay 20 at 11:20 AM | msn.comRegeneron to Acquire 23andMe for $256MMay 20 at 11:20 AM | cheddar.comRegeneron Pharmaceuticals to buy 23andMe for $256MMay 20 at 11:20 AM | msn.comPharmaceutical company Regeneron buying 23andMe for $256 millionMay 20 at 11:20 AM | msn.com23andMe sold in bankruptcy: What it means for your DNA dataMay 20 at 11:20 AM | msn.comPharmalittle: We’re reading about Regeneron buying 23andMe, the Novavax Covid shot, and moreMay 19 at 1:29 PM | statnews.comYour 23andMe data is getting a new owner. Here's how to delete your account.May 19 at 1:29 PM | msn.comBiotechnology company Regeneron buying 23andMe for $256 millionMay 19 at 9:00 AM | marketbeat.comRegeneron to buy bankrupt DNA testing firm 23andMe for $256 millionMay 19 at 8:28 AM | msn.comRegeneron to buy 23andMe for $256M in court-supervised saleMay 19 at 8:28 AM | msn.comRegeneron plans to buy 23andMe for $256MMay 19 at 8:28 AM | endpts.comRegeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised SaleMay 19 at 8:28 AM | finance.yahoo.comHow to Remove Your Private Data, Including DNA, from the Bankrupted 23andMe DatabaseMay 19 at 8:28 AM | thedroidguy.comAre You Eligible for 23andMe's $30 Million Data Breach Settlement? Find Out HereMay 17, 2025 | cnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeME and EML Company DescriptionsEastern NASDAQ:EML$23.26 -0.53 (-2.23%) As of 05/20/2025 04:00 PM EasternThe Eastern Company designs, manufactures, and sells engineered solutions to industrial markets in the United States and internationally. The company offers turnkey returnable packaging solutions, which are used in the assembly processes of vehicles, aircraft, and durable goods, as well as in production processes of plastic packaging products, packaged consumer goods, and pharmaceuticals; designs and manufactures blow mold tools and injection blow mold tooling products, and 2-step stretch blow molds and related components for the stretch blow molding industry; and supplies blow molds and change parts to the food, beverage, healthcare, and chemical industries. It also provides rotary latches, compression latches, draw latches, hinges, camlocks, key switches, padlocks, and handles; and development and program management services for custom electromechanical and mechanical systems for original equipment manufacturers (OEMs) and customer applications. In addition, the company designs and manufactures proprietary vision technology for OEMs and aftermarket applications, as well as offers aftermarket components to the heavy- and medium-duty truck, motorhome, and bus markets. The Eastern Company was founded in 1858 and is based in Shelton, Connecticut.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Viking Holdings Posts Strong Q1, Eyes Growth Ahead 2 Reasons Netflix’s 40% Rally Is Far From Over Hims & Hers Stock Chart Points to Strong Bullish Continuation Boeing Landed New Deals With China and the Saudis for More Upside CrowdStrike’s Rally Faces a Test—Here’s Why That’s Good NVIDIA-Backed CoreWeave Jumps 28%: Is It The Next Great AI Buy? UnitedHealth Insiders Double Down: Is UNH Stock a Value Play? Walmart Stock Holds as Tariff Risk Spurs Support Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
